Shanghai's EpimAb Forms Bi-Specific mAb Partnership with Kymab
October 11, 2016 at 09:12 AM EDT
EpimAb Biotherapeutics, a Shanghai startup, announced a cross-licensing and development deal with Kymab of the UK to develop bispecific therapeutic antibodies against several immuno-oncology targets. The partnership will use EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, which can generate multiple bispecific antibodies, and combine it with antibodies from Kymab’s Kymouse platform. EpimAb will own rights to the bispecifics in China; Kymab will have rights for the rest of the world. Each company will receive milestones and royalties for the other's programs. Further financial details were not disclosed. More details.... Share this with colleagues: // //